Back to top
more

MorphoSys (MOR)

(Delayed Data from NSDQ)

$18.13 USD

18.13
116,525

+0.08 (0.44%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $18.13 0.00 (0.00%) 6:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

by Zacks Equity Research

Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

by Zacks Equity Research

Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.

Novartis (NVS) to Undertake Job Cuts in Development Department

by Zacks Equity Research

Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why buying Entera Bio (ENTX) stock now may turn out to be a prudent move.

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

by Zacks Equity Research

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

by Zacks Equity Research

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.

J&J's (JNJ) $13.1B Shockwave Deal to Boost MedTech Cardio

by Zacks Equity Research

J&J's (JNJ) proposed acquisition of Shockwave Medical (SWAV) is expected to strengthen its Medtech cardiovascular portfolio.

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

by Zacks Equity Research

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Here's Why Amgen (AMGN) Stock is Outperforming the Industry

by Zacks Equity Research

Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and Enbrel

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

by Zacks Equity Research

AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.

AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod

by Zacks Equity Research

FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

by Zacks Equity Research

Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.

AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication

by Zacks Equity Research

FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.

Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.

Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why

by Zacks Equity Research

Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

by Zacks Equity Research

Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does MorphoSys AG Unsponsored ADR (MOR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Freshpet, NVIDIA, QuantaSing in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

What Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does MorphoSys AG Unsponsored ADR (MOR) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO

by Zacks Equity Research

Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO are included in this Analyst Blog.

Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More

by Zacks Equity Research

Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.

Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug

by Zacks Equity Research

Novartis (NVS) announces an agreement to acquire Germany-based MorphoSys AG and add the latter's late-stage candidate pelabresib to its pipeline.

Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates

by Zacks Equity Research

Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.

MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study

by Zacks Equity Research

Though data from the late study shows that treatment with MorphoSys' (MOR) combination therapy met its primary goal, it did not meet a secondary endpoint.